# OptiBiotix Health plc Creates potential to generate revenues across numerous territories

- Link: https://www.directorstalkinterviews.com/optibiotix-health-plc-creates-potential-generate-revenues-across-numerous-territories/412724695
- Published: 2017-03-01T07:06:51+00:00
- Author: Giles Arbor

**OptiBiotix Health plc** (LON:OPTI), a life sciences business developing compounds
to tackle obesity, high cholesterol, diabetes and skin care, announced today its
plans to launch products containing its cholesterol reducing strain (LPLDL®) at 
the Vitafoods Europe Trade Show in Geneva on the 9-11 May 2017. The trade show provides
opportunities to connect with 16,500 industry decision makers from the supplements,
nutraceutical, functional food and beverage industries. The event is viewed as one
of the world’s leading trade fairs for the food and drinks industry.

OptiBiotix will be launching the first of its range of heart health products including:-

· CholBiome™: a proprietary formulation containing LPLDL® to reduce cholesterol 
levels and blood pressure

· CardioBiome™: a proprietary formulation containing LPLDL® to reduce a wide range
of cardiovascular disease factors and improve long term heart health

The Company will also exhibit its SlimBiome® weight management technology in the
New Products Zone at Vitafoods. This is the first time this product has been exhibited
to an industry audience outside the UK.

The launch of heart health products follows a period in which OptiBiotix has been
extending its patent portfolio, registering new trademarks (e.g. LPLDL®, Cholbiome
™, Cardiobiome™) and presenting its science for peer review in publications and 
at scientific conferences. This has paralleled discussions with manufacturers, formulators
and distribution partners to develop a range of product formulations to meet different
application needs in international markets. The overall aim of this work has been
to increase industry awareness of LPLDL® to develop numerous opportunities with 
national and international partners who have rights to specific formulations and
presentations in different territories. This could create the potential for revenue
streams at multiple points in the value chain including sale of the strain as an
ingredient by manufacturers and royalties from the sales of higher value white label
formulations and branded products.

The launch of CholBiome™ and CardioBiome™ at Vitafoods is the first of a number 
of heart health formulations being licensed to manufacturing and formulation partners
for distribution and sale into the European market. Discussions are progressing 
with corporate partners for the manufacture and distribution of products containing
LPLDL® in the US, Asian and other international markets.

> **Stephen O’Hara, CEO of OptiBiotix Health plc, commented:** “OptiBiotix has made
> significant progress in developing, protecting, testing and raising industry awareness
> of its LPLDL® cholesterol and blood pressure reducing strain. This has created
> a high level of interest in commercialising LPLDL® both as a raw ingredient and
> as a component in higher value branded products. This creates the potential to
> generate revenues for different formulations and presentations across numerous
> territories at multiple points in the value chain with a mixture of national and
> international partners.”

Share on: